Latest News and Press Releases

– Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML – – $2.1 million KOMZIFTI net product revenue for the period from...

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva’s anti-IL-15 candidate...

VICTORIA, Seychelles, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Bitget has released a comparative review examining trading fees across leading cryptocurrency exchanges, offering a structured overview of how...

One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026 ...

Castle today announced certain unaudited preliminary performance results for the fourth quarter and year ended Dec. 31, 2025.

Las Vegas, NV, Jan. 11, 2026 (GLOBE NEWSWIRE) -- As the doors opened at the Venetian Expo for CES 2026, a clear trend emerged: the world is moving past text-based chatbots. FIRSTHABIT, an education...

Phase 1/2a study with lead Radio-DARPin MP0712 initiated; first patient dosing expected Q1 2026, initial data anticipated in 2026Full imaging and dosimetry data from MP0712 compassionate care program...

Exagen Inc. announces select preliminary unaudited financial results for the fourth quarter and full year 2025, in line with prior guidance.

Las Vegas, NV, Jan. 11, 2026 (GLOBE NEWSWIRE) -- At CES 2026, Speediance introduced a fully immersive smart home gym experience that allowed attendees to step directly into the future of fitness....

Preliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million Robust clinical pipeline with multibillion dollar opportunities and strong balance sheet for sustained growth PITTSBURGH,...